[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618373":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":25,"responsibleParty":99,"collaborators":19,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":19,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":109,"maxAge":19,"enrollmentInfo":110,"targetDuration":19,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":28,"whyStopped":19,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"Celldex Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CDX-622","EXPERIMENTAL","Eligible participants will receive a single dose",[13],"Drug: CDX-622",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Administered Intravenously",[9],null,[21],{"name":5,"role":22,"phone":23,"phoneExt":19,"email":24},"CONTACT","844-723-9363","clinicaltrials@celldex.com",[26,47,66,80],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"University of California, San Francisco","RECRUITING","San Francisco","California","94143","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-122.41942,37.77493,{"lat":38,"lon":37},[41,44],{"name":42,"role":22,"phone":19,"phoneExt":19,"email":43},"Mariana Mosqueda","Mariana.Mosqueda@ucsf.edu",{"name":45,"role":22,"phone":19,"phoneExt":19,"email":46},"Christine Nguyen","Christine.Nguyen@ucsf.edu",{"facility":48,"status":28,"city":49,"state":50,"zip":51,"country":32,"countryCode":33,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"The University of Kansas Medical Center","Kansas City","Kansas","66160",{"type":35,"coordinates":53},[54,55],-94.62746,39.11417,{"lat":55,"lon":54},[58,62],{"name":59,"role":22,"phone":60,"phoneExt":19,"email":61},"Jamie Quigley, RRT, RPFT, AE-C, CCRC","913-574-3036","jtroxel@kumc.edu",{"name":63,"role":22,"phone":64,"phoneExt":19,"email":65},"Victoria Dorman, CCRC","913-588-1833","vdorman@kumc.edu",{"facility":67,"status":28,"city":68,"state":69,"zip":70,"country":32,"countryCode":33,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Brigham and Women's Hospital","Boston","Massachusetts","02115",{"type":35,"coordinates":72},[73,74],-71.05977,42.35843,{"lat":74,"lon":73},[77],{"name":78,"role":22,"phone":19,"phoneExt":19,"email":79},"Maria Angeles Cinelli","arc@bwh.harvard.edu",{"facility":81,"status":28,"city":82,"state":83,"zip":84,"country":32,"countryCode":33,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"University of Pittsburgh Asthma and Environmental Lung Health Institute at UPMC","Pittsburgh","Pennsylvania","15213",{"type":35,"coordinates":86},[87,88],-79.99589,40.44062,{"lat":88,"lon":87},[91,95],{"name":92,"role":22,"phone":93,"phoneExt":19,"email":94},"Logan Sullivan","412-639-0585","sullivanlt@upmc.edu",{"name":96,"role":22,"phone":97,"phoneExt":19,"email":98},"Taylor Nee","412-463-7728","neet2@upmc.edu",{"type":100,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100618373","phase-1-a-study-of-cdx-622-in-participants-with-mild-to-moderate-asthma-100618373",false,"NCT07330778","A Study of CDX-622 in Participants With Mild to Moderate Asthma","An Open-Label, Single-Dose Study to Assess the Safety, Pharmacodynamics, and Pharmacokinetics of CDX-622 in Adults With Mild to Moderate Asthma","Key Inclusion Criteria:\n\n1. Males and females, ≥ 18 years of age\n2. Diagnosis of mild to moderate asthma for at least 12 months\n3. Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted normal\n4. Airway reversibility ≥ 12% and 200 mL improvement in FEV1\n5. Both males and females of child-bearing potential must agree to use contraception during the study and for 150 days after treatment\n6. Willing and able to comply with all study requirements and procedures\n\nKey Exclusion Criteria:\n\n1. Females who are pregnant or nursing\n2. Pulmonary disease other than asthma\n3. Systemic diseases with elevated eosinophils other than asthma\n4. Hospitalization for treatment of asthma in the past 12 months or required oral corticosteroids due to asthma within the past 6 months\n5. History of needing ventilator support due to asthma\n6. Current nasal polyps\n7. Severe or uncontrolled asthma\n8. History of smoking or vaping within the past 6 months\n9. Tuberculosis, hepatitis B or C virus, or HIV\n10. Immunomodulating biologic therapies within the past 3 months for non-extended half-life biologics.\n11. Prior receipt of TSLP or KIT inhibitors such as tezepelumab or briquilimab\n\nAdditional protocol defined inclusion and exclusion criteria could apply.","ALL","18 Years",{"count":111,"type":112},12,"ESTIMATED","INTERVENTIONAL",[115],"PHASE1","This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.",[118],"Mild to Moderate Asthma",[120,121,9],"Asthma","Mild to moderate","2026-06-30",{"date":124,"type":125},"2026-07-02","ACTUAL",{"date":127,"type":125},"2026-06-01",{"date":129,"type":112},"2027-03",{"name":5,"class":6},4]